News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Urigen Pharmaceuticals, Inc. and Hyaluron Contract Manufacturing (HCM) Enter into Drug Development Agreement for URG101


12/5/2007 1:09:09 PM

BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP, http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, and Hyaluron Contract Manufacturing, Inc. (www.hyaluron.com), a leading provider of aseptic manufacturing services to companies in the pharmaceutical and biotechnology industries, have established a partnership to develop URG101, Urigen’s proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES